Skip to NavigationSkip to content

Top Ten most popular articles on this week

Published on 10/11/17 at 11:01am

Friday again, and we bring you the most read articles on our site this week - one of which was the startling news that 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or more.

Recent staff rumblings at GSK proved to be very popular with our readers this week, as news emerged that GSK's Head of R&D is to leave the company to become the UK Government's Chief Scientific Adviser. In addition, the company has also welcomed Hal Barron as its Chief Scientific Officer and President of R&D, awarding him a position on the board of the company.

The most popular piece this week, however, was our in-depth feature on the exciting world of CAR-T therapy, and how recent approvals could mean big things for the future of cancer treatment.

Check out the week's ten most popular articles on now!

10. Gene therapy helps child regrow 80% of skin

A young child has been brought back from the verge of death after an experimental combination of stem cell and gene therapy procedures managed to repair his badly damaged skin.

9. 17,000 English patients are surviving Stage 4 cancer for two years or more, new data shows

At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or more, according to new data revealed by Macmillan Cancer Support and Public Health England’s (PHE) National Cancer Registration and Analysis Service.

8. Witty to lead way in fast-tracking medicine through UK system

The UK government has announced its response to the Accelerated Access Review that was published last year, with former GSK CEO tasked to lead a panel in proposing a handful of drugs and devices to be sped through the system.

7. Merck KGaA posts promising osteoarthritis data

Merck KGaA released results of its osteoarthritis treatment that could become the first treatment to successfully slow or halt the disease.

6. NHS England seals access deals with big pharma for breast cancer and MS

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both multiple sclerosis and breast cancer, it has emerged.

5. Novartis aims for CAR-T double-approval in Europe

Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma (DLBCL) for its CAR-T treatment, Kymriah, now the company has gone to the EMA hoping to secure two indications at the same time.

4. Clinical trial transparency: Letting the light in

Transparency is becoming important across a whole range of industries but, for the pharmaceutical industry, it can mean life or death. Ben Hargreaves examines the push for more clinical trial data to be revealed so that research can continue to move forward and to stop unfavourable results becoming lost.

3. GSK’s R&D head to move on after shift in focus

There has been a raft of changes at senior levels of GSK since Emma Walmsley took over the role from Andrew Witty, with the latest seeing its R&D head set to leave to become the UK government’s Chief Scientific Adviser.

2. GSK indicates a return to oncology by appointing Roche veteran

GSK, under its new CEO, has made most of its waves recently not with approvals but with high-profile appointments, and it continued in this trend with the appointment Hal Barron.

1. CAR-T is bringing true precision to the fight against cancer

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment is changed forever.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches